Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...